1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market Segmentations
2.
Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4.
Voice of Customer
5. Global Compounding
Chemotherapy Market Outlook
5.1.
Market Size & Forecast
5.1.1. By Value
5.2.
Market Share & Forecast
5.2.1. By Drug Type
(Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies,
Supportive Care Drugs)
5.2.2. By Route of
Administration (Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal)
5.2.3. By Cancer Type
(Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukemia,
Lymphoma, Others)
5.2.4. By Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.5. By Company (2022)
5.2.6. By Region
5.3.
Market Map
6. North America Compounding
Chemotherapy Market Outlook
6.1.
Market Size & Forecast
6.1.1. By Value
6.2.
Market Share & Forecast
6.2.1. By Drug Type
6.2.2. By Route of Administration
6.2.3. By Cancer Type
6.2.4. By Distribution Channel
6.2.5. By Country
6.3.
North America: Country Analysis
6.3.1. United States Compounding
Chemotherapy Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Drug Type
6.3.1.2.2.
By Route of Administration
6.3.1.2.3.
By Cancer Type
6.3.1.2.4.
By Distribution Channel
6.3.2. Mexico Compounding
Chemotherapy Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Drug Type
6.3.2.2.2.
By Route of Administration
6.3.2.2.3.
By Cancer Type
6.3.2.2.4.
By Distribution Channel
6.3.3. Canada Compounding
Chemotherapy Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Drug Type
6.3.3.2.2.
By Route of Administration
6.3.3.2.3.
By Cancer Type
6.3.3.2.4.
By Distribution Channel
7. Europe Compounding
Chemotherapy Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value
7.2.
Market Share & Forecast
7.2.1. By Drug Type
7.2.2. By Route of Administration
7.2.3. By Cancer Type
7.2.4. By Distribution Channel
7.2.5. By Country
7.3.
Europe: Country Analysis
7.3.1. France Compounding
Chemotherapy Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Drug Type
7.3.1.2.2.
By Route of Administration
7.3.1.2.3.
By Cancer Type
7.3.1.2.4.
By Distribution Channel
7.3.2. Germany Compounding
Chemotherapy Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Drug Type
7.3.2.2.2.
By Route of Administration
7.3.2.2.3.
By Cancer Type
7.3.2.2.4.
By Distribution Channel
7.3.3. United Kingdom Compounding
Chemotherapy Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Drug Type
7.3.3.2.2.
By Route of Administration
7.3.3.2.3.
By Cancer Type
7.3.3.2.4.
By Distribution Channel
7.3.4. Italy Compounding
Chemotherapy Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Drug Type
7.3.4.2.2.
By Route of Administration
7.3.4.2.3.
By Cancer Type
7.3.4.2.4.
By Distribution Channel
7.3.5. Spain Compounding
Chemotherapy Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Drug Type
7.3.5.2.2.
By Route of Administration
7.3.5.2.3.
By Cancer Type
7.3.5.2.4.
By Distribution Channel
8. Asia-Pacific Compounding
Chemotherapy Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By Drug Type
8.2.2. By Route of Administration
8.2.3. By Cancer Type
8.2.4. By Distribution Channel
8.2.5. By Country
8.3.
Asia-Pacific: Country Analysis
8.3.1. China Compounding
Chemotherapy Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Drug Type
8.3.1.2.2.
By Route of Administration
8.3.1.2.3.
By Cancer Type
8.3.1.2.4.
By Distribution Channel
8.3.2. India Compounding
Chemotherapy Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Drug Type
8.3.2.2.2.
By Route of Administration
8.3.2.2.3.
By Cancer Type
8.3.2.2.4.
By Distribution Channel
8.3.3. South Korea Compounding
Chemotherapy Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Drug Type
8.3.3.2.2.
By Route of Administration
8.3.3.2.3.
By Cancer Type
8.3.3.2.4.
By Distribution Channel
8.3.4. Japan Compounding
Chemotherapy Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Drug Type
8.3.4.2.2.
By Route of Administration
8.3.4.2.3.
By Cancer Type
8.3.4.2.4.
By Distribution Channel
8.3.5. Australia Compounding
Chemotherapy Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Drug Type
8.3.5.2.2.
By Route of Administration
8.3.5.2.3.
By Cancer Type
8.3.5.2.4.
By Distribution Channel
9. South America Compounding
Chemotherapy Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value
9.2.
Market Share & Forecast
9.2.1. By Drug Type
9.2.2. By Route of Administration
9.2.3. By Cancer Type
9.2.4. By Distribution Channel
9.2.5. By Country
9.3.
South America: Country Analysis
9.3.1. Brazil Compounding
Chemotherapy Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Drug Type
9.3.1.2.2.
By Route of Administration
9.3.1.2.3.
By Cancer Type
9.3.1.2.4.
By Distribution Channel
9.3.2. Argentina Compounding
Chemotherapy Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Drug Type
9.3.2.2.2.
By Route of Administration
9.3.2.2.3.
By Cancer Type
9.3.2.2.4.
By Distribution Channel
9.3.3. Colombia Compounding
Chemotherapy Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Drug Type
9.3.3.2.2.
By Route of Administration
9.3.3.2.3.
By Cancer Type
9.3.3.2.4.
By Distribution Channel
10. Middle East and
Africa Compounding Chemotherapy Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value
10.2.
Market Share & Forecast
10.2.1. By Drug Type
10.2.2. By Route of Administration
10.2.3. By Cancer Type
10.2.4. By Distribution Channel
10.2.5.
By Country
10.3.
MEA: Country Analysis
10.3.1.
South Africa Compounding Chemotherapy Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Drug Type
10.3.1.2.2.
By Route of Administration
10.3.1.2.3.
By Cancer Type
10.3.1.2.4.
By Distribution Channel
10.3.2.
Saudi Arabia Compounding Chemotherapy Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Drug Type
10.3.2.2.2.
By Route of Administration
10.3.2.2.3.
By Cancer Type
10.3.2.2.4.
By Distribution Channel
10.3.3.
UAE Compounding Chemotherapy market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Drug Type
10.3.3.2.2.
By Route of Administration
10.3.3.2.3.
By Cancer Type
10.3.3.2.4.
By Distribution Channel
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
12.1.
Recent Developments
12.2.
Product Launches
12.3.
Mergers & Acquisitions
13.
PESTLE Analysis
14. Porter’s Five Forces
Analysis
14.1.
Competition in the Industry
14.2.
Potential of New Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute Product
15.
Competitive Landscape
15.1. Pfizer Inc.
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (In case of listed companies)
15.1.5. Recent Developments
15.1.6. SWOT Analysis
15.2. Baxter International
Inc.
15.2.1. Business Overview
15.2.2. Company Snapshot
15.2.3. Products & Services
15.2.4. Financials (In case of listed companies)
15.2.5. Recent Developments
15.2.6. SWOT Analysis
15.3. Grifols SA
15.3.1. Business Overview
15.3.2. Company Snapshot
15.3.3. Products & Services
15.3.4. Financials (In case of listed companies)
15.3.5. Recent Developments
15.3.6. SWOT Analysis
15.4. Comecer S.P.A.
15.4.1. Business Overview
15.4.2. Company Snapshot
15.4.3. Products & Services
15.4.4. Financials (In case of listed companies)
15.4.5. Recent Developments
15.4.6. SWOT Analysis
15.5. Arxium Inc.
15.5.1. Business Overview
15.5.2. Company Snapshot
15.5.3. Products & Services
15.5.4. Financials (In case of listed companies)
15.5.5. Recent Developments
15.5.6. SWOT Analysis
15.6. Dedalus Group
15.6.1. Business Overview
15.6.2. Company Snapshot
15.6.3. Products & Services
15.6.4. Financials (In case of listed companies)
15.6.5. Recent Developments
15.6.6. SWOT Analysis
15.7. B. Braun Melsungen
AG
15.7.1. Business Overview
15.7.2. Company Snapshot
15.7.3. Products & Services
15.7.4. Financials (In case of listed companies)
15.7.5. Recent Developments
15.7.6. SWOT Analysis
15.8. Omnicell
Technologies Inc.
15.8.1. Business Overview
15.8.2. Company Snapshot
15.8.3. Products & Services
15.8.4. Financials (In case of listed companies)
15.8.5. Recent Developments
15.8.6. SWOT Analysis
15.9. The Metrix Company
15.9.1. Business Overview
15.9.2. Company Snapshot
15.9.3. Products & Services
15.9.4. Financials (In case of listed companies)
15.9.5. Recent Developments
15.9.6. SWOT Analysis
15.10.Sterline S.R.L.
15.10.1.
Business
Overview
15.10.2.
Company
Snapshot
15.10.3.
Products &
Services
15.10.4.
Financials (In
case of listed companies)
15.10.5.
Recent
Developments
15.10.6.
SWOT Analysis
16. Strategic Recommendations